Cell Therapy Processing Market by Offering Type (Products, Services, and Software), and Application (Cardiovascular Devices, Bone Repair, Neurological Disorders, Skeletal Muscle Repair, Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
The global cell therapy processing market was valued at $1,695 million in 2018, and is projected to reach $12,062 million by 2026, registering a CAGR of 27.80% from 2019 to 2026.
Cell therapy is the administration of living cells to replace a missing cell type or to offer a continuous source of a necessary factor to achieve a truly meaningful therapeutic outcome. There are different forms of cell therapy, ranging from transplantation of cells derived from an individual patient or from another donor. The manufacturing process of cell therapy requires the use of different products such as cell lines and instruments. These cell therapies are used for the treatment of various diseases such as cardiovascular disease and neurological disorders.
Increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, increase in the R&D for the advancement in the research associated with cell therapy, increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and rise in understanding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) & induced pluripotent stem (iPS) cells are the key factors that fuel the growth of the cell therapy processing market. Moreover, increase in a number of clinical studies relating to the development of cell therapy processing, rise in adoption of regenerative drug, introduction of novel technologies for cell therapy processing, increase in government investments for cell-based research, increase in number of GMP-certified production facilities, large number of oncology-oriented cell-based therapy clinical trials, and rise in the development of allogeneic cell therapy are other factors that augment the growth of the market. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market.
The cell therapy processing market is segmented into offering type, application, and region. By type, the market is categorized into products, services, and software. The application covered in the segment include cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
KEY BENEFITS FOR STAKEHOLDERS
By Offering Type
Cell therapy is the administration of living cells to replace a missing cell type or to offer a continuous source of a necessary factor to achieve a truly meaningful therapeutic outcome. There are different forms of cell therapy, ranging from transplantation of cells derived from an individual patient or from another donor. The manufacturing process of cell therapy requires the use of different products such as cell lines and instruments. These cell therapies are used for the treatment of various diseases such as cardiovascular disease and neurological disorders.
Increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, increase in the R&D for the advancement in the research associated with cell therapy, increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and rise in understanding of the role of stem cells in inducing development of functional lung cells from both embryonic stem cells (ESCs) & induced pluripotent stem (iPS) cells are the key factors that fuel the growth of the cell therapy processing market. Moreover, increase in a number of clinical studies relating to the development of cell therapy processing, rise in adoption of regenerative drug, introduction of novel technologies for cell therapy processing, increase in government investments for cell-based research, increase in number of GMP-certified production facilities, large number of oncology-oriented cell-based therapy clinical trials, and rise in the development of allogeneic cell therapy are other factors that augment the growth of the market. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market.
The cell therapy processing market is segmented into offering type, application, and region. By type, the market is categorized into products, services, and software. The application covered in the segment include cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
By Offering Type
- Products
- Services
- Software
- Cardiovascular Devices
- Bone Repair
- Neurological Disorders
- Skeletal Muscle Repair
- Cancer
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa
- Cell Therapies Pty Ltd
- Invitrx Inc.
- Lonza Ltd
- Merck & Co., Inc. (FloDesign Sonics)
- NantWorks, LLC
- Neurogeneration, Inc.
- Novartis AG
- Plasticell Ltd.
- Regeneus Ltd
- StemGenex, Inc.
- Beckman Coulter, Inc.
- Stemcell Technologies
- MiltenyiBiotec GmbH
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the incidence of cardiovascular diseases
3.4.1.2. Rise in the demand for chimeric antigen receptor (CAR) t cell therapy
3.4.1.3. Increase in the development of stem cell therapy approaches
3.4.2. Restraint
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis
CHAPTER 4: CELL THERAPY PROCESSING MARKET, BY OFFERING TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Products
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Services
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Software
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: GLOBAL CELL THERAPY PROCESSING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cardiovascular diseases
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Bone Repair
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Neurological Disorders
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Skeletal Muscle Repair
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Other Applications
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
CHAPTER 6: CELL THERAPY PROCESSING MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America CELL THERAPY PROCESSING market, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by offering type
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by OFFERING TYPE
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by OFFERING TYPE
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by offering type
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe cell therapy processing market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by OFFERING TYPE
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by OFFERING TYPE
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by OFFERING TYPE
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by OFFERING TYPE
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by OFFERING TYPE
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by OFFERING TYPE
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by OFFERING TYPE
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific CELL THERAPY PROCESSING market, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by offering type
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by offering type
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by OFFERING TYPE
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by OFFERING TYPE
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by offering type
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA CELL THERAPY PROCESSING market, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by OFFERING TYPE
6.5.2.1.2. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle East market size and forecast, by OFFERING TYPE
6.5.2.2.2. Middle East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by offering type
6.5.2.3.2. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by OFFERING TYPE
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Cell Therapies Pty Ltd
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.2. INVITRX INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. LONZA LTD
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Merck & Co., Inc. (FloDesign Sonics)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. NantWorks, LLC
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.6. Neurogeneration, Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.7. Novartis AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Plasticell Ltd.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Key strategic moves and developments
7.9. REGENEUS LTD
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. StemGenex, Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the incidence of cardiovascular diseases
3.4.1.2. Rise in the demand for chimeric antigen receptor (CAR) t cell therapy
3.4.1.3. Increase in the development of stem cell therapy approaches
3.4.2. Restraint
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis
CHAPTER 4: CELL THERAPY PROCESSING MARKET, BY OFFERING TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Products
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Services
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Software
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: GLOBAL CELL THERAPY PROCESSING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cardiovascular diseases
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Bone Repair
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Neurological Disorders
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Skeletal Muscle Repair
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Other Applications
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
CHAPTER 6: CELL THERAPY PROCESSING MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America CELL THERAPY PROCESSING market, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by offering type
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by OFFERING TYPE
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by OFFERING TYPE
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by offering type
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe cell therapy processing market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by OFFERING TYPE
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by OFFERING TYPE
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by OFFERING TYPE
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by OFFERING TYPE
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by OFFERING TYPE
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by OFFERING TYPE
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by OFFERING TYPE
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific CELL THERAPY PROCESSING market, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by offering type
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by offering type
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by OFFERING TYPE
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by OFFERING TYPE
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by offering type
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA CELL THERAPY PROCESSING market, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by OFFERING TYPE
6.5.2.1.2. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle East market size and forecast, by OFFERING TYPE
6.5.2.2.2. Middle East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by offering type
6.5.2.3.2. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by OFFERING TYPE
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Cell Therapies Pty Ltd
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.2. INVITRX INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. LONZA LTD
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Merck & Co., Inc. (FloDesign Sonics)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. NantWorks, LLC
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.6. Neurogeneration, Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.7. Novartis AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Plasticell Ltd.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Key strategic moves and developments
7.9. REGENEUS LTD
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. StemGenex, Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
LIST OF TABLES
TABLE 01. CELL THERAPY PROCESSING MARKET, BY OFFERING TYPE, 2018–2026 ($MILLION)
TABLE 02. CELL THERAPY PROCESSING MARKET FOR PRODUCT OFFERING, BY REGION 2018–2026 ($MILLION)
TABLE 03. CELL THERAPY PROCESSING MARKET FOR SERVICES, BY REGION 2018–2026 ($MILLION)
TABLE 04. CELL THERAPY PROCESSING MARKET FOR SOFTWARE, BY REGION 2018–2026 ($MILLION)
TABLE 05. CELL THERAPY PROCESSING MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 06. CELL THERAPY PROCESSING MARKET FOR CARDIOVASCULAR DISEASE, BY REGION 2018–2026 ($MILLION)
TABLE 07. CELL THERAPY PROCESSING MARKET FOR BONE REPAIR, BY REGION 2018–2026 ($MILLION)
TABLE 08. CELL THERAPY PROCESSING MARKET FOR NEUROLOGICAL DISORDERS, BY REGION 2018–2026 ($MILLION)
TABLE 09. CELL THERAPY PROCESSING MARKET FOR SKELETAL MUSCLE REPAIR, BY REGION 2018–2026 ($MILLION)
TABLE 10. CELL THERAPY PROCESSING MARKET FOR CANCER, BY REGION 2018–2026 ($MILLION)
TABLE 11. CELL THERAPY PROCESSING MARKET FOR SKELETAL MUSCLE REPAIR, BY REGION 2018–2026 ($MILLION)
TABLE 12. CELL THERAPY PROCESSING MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 13. NORTH AMERICA CELL THERAPY PROCESSING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14. U.S. CELL THERAPY PROCESSING MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 15. U.S. CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 16. CANADA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 17. CANADA INFLUENZA TREATMENT CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 18. MEXICO CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 19. MEXICO CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 20. NORTH AMERICA CELL THERAPY PROCESSING REVENUE, BY OFFERING TYPE, 2019–2026($MILLION)
TABLE 21. NORTH AMERICA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 22. EUROPE CELL THERAPY PROCESSING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 23. GERMANY CELL THERAPY PROCESSING MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 24. GERMANY CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 25. FRANCE CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 26. FRANCE CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 27. UK CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 28. UK CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 29. ITALY CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 30. ITALY CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 31. SPAIN CELL THERAPY PROCESSING REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 32. SPAIN CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 33. REST OF EUROPE CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 34. REST OF EUROPE CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 35. EUROPE CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026($MILLION)
TABLE 36. EUROPE CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 37. ASIA-PACIFIC CELL THERAPY PROCESSING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 38. JAPAN CELL THERAPY PROCESSING MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 39. JAPAN CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 40. CHINA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 41. CHINA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 42. INDIA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 43. INDIA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 44. REST OF ASIA-PACIFIC CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 46. ASIA-PACIFIC CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026($MILLION)
TABLE 47. ASIA-PACIFIC CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 48. LAMEA CELL THERAPY PROCESSING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 49. LATIN AMERICA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 50. LATIN AMERICA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 51. MIDDLE EAST CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 52. MIDDLE EAST CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 53. AFRICA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 54. AFRICA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 55. LAMEA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026($MILLION)
TABLE 56. LAMEA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 57. CELL THERAPIES: COMPANY SNAPSHOT
TABLE 58. CELL THERAPIES: OPERATING SEGMENTS
TABLE 59. CELL THERAPIES: PRODUCT PORTFOLIO
TABLE 60. INVITRX THERAPEUTICS: COMPANY SNAPSHOT
TABLE 61. INVITRX THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 62. LONZA.: COMPANY SNAPSHOT
TABLE 63. LONZA.: OPERATING SEGMENTS
TABLE 64. LONZA: PRODUCT PORTFOLIO
TABLE 65. MERCK: COMPANY SNAPSHOT
TABLE 66. MERCK: OPERATING SEGMENTS
TABLE 67. MERCK: PRODUCT PORTFOLIO
TABLE 68. NANTWORKS: COMPANY SNAPSHOT
TABLE 69. NANTWORKS: PRODUCT PORTFOLIO
TABLE 70. NEUROGENERATION: COMPANY SNAPSHOT
TABLE 71. NEUROGENERATION: PRODUCT PORTFOLIO
TABLE 72. NOVARTIS: COMPANY SNAPSHOT
TABLE 73. NOVARTIS: OPERATING SEGMENTS
TABLE 74. NOVARTIS: PRODUCT PORTFOLIO
TABLE 75. PLASTICELL: COMPANY SNAPSHOT
TABLE 76. PLASTICELL: PRODUCT PORTFOLIO
TABLE 77. REGENEUS: COMPANY SNAPSHOT
TABLE 78. REGENEUS: OPERATING SEGMENTS
TABLE 79. REGENEUS LTD: PRODUCT PORTFOLIO
TABLE 80. STEMGENEX: COMPANY SNAPSHOT
TABLE 81. STEMGENEX: PRODUCT PORTFOLIO
TABLE 01. CELL THERAPY PROCESSING MARKET, BY OFFERING TYPE, 2018–2026 ($MILLION)
TABLE 02. CELL THERAPY PROCESSING MARKET FOR PRODUCT OFFERING, BY REGION 2018–2026 ($MILLION)
TABLE 03. CELL THERAPY PROCESSING MARKET FOR SERVICES, BY REGION 2018–2026 ($MILLION)
TABLE 04. CELL THERAPY PROCESSING MARKET FOR SOFTWARE, BY REGION 2018–2026 ($MILLION)
TABLE 05. CELL THERAPY PROCESSING MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 06. CELL THERAPY PROCESSING MARKET FOR CARDIOVASCULAR DISEASE, BY REGION 2018–2026 ($MILLION)
TABLE 07. CELL THERAPY PROCESSING MARKET FOR BONE REPAIR, BY REGION 2018–2026 ($MILLION)
TABLE 08. CELL THERAPY PROCESSING MARKET FOR NEUROLOGICAL DISORDERS, BY REGION 2018–2026 ($MILLION)
TABLE 09. CELL THERAPY PROCESSING MARKET FOR SKELETAL MUSCLE REPAIR, BY REGION 2018–2026 ($MILLION)
TABLE 10. CELL THERAPY PROCESSING MARKET FOR CANCER, BY REGION 2018–2026 ($MILLION)
TABLE 11. CELL THERAPY PROCESSING MARKET FOR SKELETAL MUSCLE REPAIR, BY REGION 2018–2026 ($MILLION)
TABLE 12. CELL THERAPY PROCESSING MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 13. NORTH AMERICA CELL THERAPY PROCESSING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14. U.S. CELL THERAPY PROCESSING MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 15. U.S. CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 16. CANADA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 17. CANADA INFLUENZA TREATMENT CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 18. MEXICO CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 19. MEXICO CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 20. NORTH AMERICA CELL THERAPY PROCESSING REVENUE, BY OFFERING TYPE, 2019–2026($MILLION)
TABLE 21. NORTH AMERICA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 22. EUROPE CELL THERAPY PROCESSING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 23. GERMANY CELL THERAPY PROCESSING MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 24. GERMANY CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 25. FRANCE CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 26. FRANCE CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 27. UK CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 28. UK CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 29. ITALY CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 30. ITALY CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 31. SPAIN CELL THERAPY PROCESSING REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 32. SPAIN CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 33. REST OF EUROPE CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 34. REST OF EUROPE CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 35. EUROPE CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026($MILLION)
TABLE 36. EUROPE CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 37. ASIA-PACIFIC CELL THERAPY PROCESSING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 38. JAPAN CELL THERAPY PROCESSING MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 39. JAPAN CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 40. CHINA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 41. CHINA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 42. INDIA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 43. INDIA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 44. REST OF ASIA-PACIFIC CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 46. ASIA-PACIFIC CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026($MILLION)
TABLE 47. ASIA-PACIFIC CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 48. LAMEA CELL THERAPY PROCESSING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 49. LATIN AMERICA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 50. LATIN AMERICA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 51. MIDDLE EAST CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 52. MIDDLE EAST CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 53. AFRICA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026 ($MILLION)
TABLE 54. AFRICA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026 ($MILLION)
TABLE 55. LAMEA CELL THERAPY PROCESSING MARKET REVENUE, BY OFFERING TYPE, 2019–2026($MILLION)
TABLE 56. LAMEA CELL THERAPY PROCESSING MARKET REVENUE, BY APPLICATION, 2019–2026($MILLION)
TABLE 57. CELL THERAPIES: COMPANY SNAPSHOT
TABLE 58. CELL THERAPIES: OPERATING SEGMENTS
TABLE 59. CELL THERAPIES: PRODUCT PORTFOLIO
TABLE 60. INVITRX THERAPEUTICS: COMPANY SNAPSHOT
TABLE 61. INVITRX THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 62. LONZA.: COMPANY SNAPSHOT
TABLE 63. LONZA.: OPERATING SEGMENTS
TABLE 64. LONZA: PRODUCT PORTFOLIO
TABLE 65. MERCK: COMPANY SNAPSHOT
TABLE 66. MERCK: OPERATING SEGMENTS
TABLE 67. MERCK: PRODUCT PORTFOLIO
TABLE 68. NANTWORKS: COMPANY SNAPSHOT
TABLE 69. NANTWORKS: PRODUCT PORTFOLIO
TABLE 70. NEUROGENERATION: COMPANY SNAPSHOT
TABLE 71. NEUROGENERATION: PRODUCT PORTFOLIO
TABLE 72. NOVARTIS: COMPANY SNAPSHOT
TABLE 73. NOVARTIS: OPERATING SEGMENTS
TABLE 74. NOVARTIS: PRODUCT PORTFOLIO
TABLE 75. PLASTICELL: COMPANY SNAPSHOT
TABLE 76. PLASTICELL: PRODUCT PORTFOLIO
TABLE 77. REGENEUS: COMPANY SNAPSHOT
TABLE 78. REGENEUS: OPERATING SEGMENTS
TABLE 79. REGENEUS LTD: PRODUCT PORTFOLIO
TABLE 80. STEMGENEX: COMPANY SNAPSHOT
TABLE 81. STEMGENEX: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL CELL THERAPY PROCESSING MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET PLAYER POSITIONING, 2018
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
FIGURE 08. HIGH INTENSITY OF RIVALRY
FIGURE 09. IMPACT ANALYSIS
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR PRODUCTS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR SERVICES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR SOFTWARE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR BONE REPAIR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR SKELETAL MUSCLE REPAIR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR SKELETAL MUSCLE REPAIR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. LONZA: NET SALES, 2016–2018 ($MILLION)
FIGURE 20. LONZA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 21. LONZA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 22. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24. MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 25. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 28. REGENEUS LTD: NET SALES, 2016–2018 ($MILLION)
FIGURE 01. GLOBAL CELL THERAPY PROCESSING MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET PLAYER POSITIONING, 2018
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
FIGURE 08. HIGH INTENSITY OF RIVALRY
FIGURE 09. IMPACT ANALYSIS
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR PRODUCTS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR SERVICES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR SOFTWARE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR BONE REPAIR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR SKELETAL MUSCLE REPAIR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR CANCER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CELL THERAPY PROCESSING MARKET FOR SKELETAL MUSCLE REPAIR, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. LONZA: NET SALES, 2016–2018 ($MILLION)
FIGURE 20. LONZA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 21. LONZA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 22. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24. MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 25. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 28. REGENEUS LTD: NET SALES, 2016–2018 ($MILLION)
